Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals

AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option

Published
10 March 2017
By
Liz Highleyman
Dutch adherence programme boosts HIV Tx success rate

Dutch researchers have developed an HIV medication adherence programme that has been successful in increasing treatment success rates by almost 18%, claiming it as the first adherence intervention in HIV care that demonstrates clinical and cost effectiveness.

Published
09 March 2017
From
Medical Brief
New antibody therapy “profoundly” successful at reducing inflammation from HIV

In a very small study of people living with HIV, a one-time antibody treatment significantly reduced the type of inflammation that can lead to heart attacks and other cardiovascular problems.

Published
09 March 2017
From
BETA blog
Dolutegravir monotherapy fails to maintain HIV viral suppression, but dolutegravir + lamivudine looks good

Dolutegravir used alone without other antiretrovirals was unable to keep viral load suppressed in some people who switched from a standard three-drug combination regimen, according to research

Published
09 March 2017
By
Liz Highleyman
Clinical Commissioning Policy: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents

TAF containing products can be made available to patients who have defined renal or bone problems or who have medical reasons why they cannot take other HIV drugs.

Published
06 March 2017
From
NHS England
Researchers report case of bone marrow transplant patient off ART for 288 days without HIV rebound

An HIV-positive bone marrow transplant recipient at the Mayo Clinic experienced prolonged viral remission lasting nearly 10 months – longer than the so-called Boston patients – after interrupting

Published
06 March 2017
By
Liz Highleyman
New HIV capsid inhibitors show high potency and prolonged activity in early studies

A novel type of antiretroviral drug that interferes with the assembly and disassembly of the HIV capsid, which encloses the genetic blueprint of the virus, may offer

Published
03 March 2017
By
Liz Highleyman
Integrase inhibitors may increase risk of IRIS in late presenters for HIV treatment

HIV integrase inhibitors such as dolutegravir and raltegravir may increase the risk of immune reconstitution inflammatory syndrome (IRIS), studies from the Netherlands and France presented

Published
01 March 2017
By
Keith Alcorn
How to Keep HIV Cure-Related Trials Ethical: The Benefit/Risk Ratio Challenge

While high or unknown risks are a mainstay of early-phase trials in areas like cancer research, cure study participants typically have a safe and efficacious alternative to those risks: remaining on antiretrovirals. Can we justify asking patients who are doing well on antiretrovirals to accept the risk and uncertainty of many HIV cure-related trials? If we cannot, we might need to give up on the hope of curing HIV, or of achieving controlled remission.

Published
22 February 2017
From
BMJ Blogs
Monoclonal antibodies show promise for HIV-positive people with limited treatment options

A pair of long-acting monoclonal antibodies that prevent HIV from entering human cells – ibalizumab and PRO 140 – may offer new treatment options for people with

Published
22 February 2017
By
Liz Highleyman

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.